Clinical Trials Logo

Clinical Trial Summary

A Phase 1, first in human (FIH), single-centre, double-blind, randomized, placebo-controlled, dose escalating trial to assess the safety and tolerability, pharmacokinetics (PK), immunogenicity and pharmacodynamics (PD) of CBS001 in healthy subjects. The study will be conducted in 2 parts: Part A: Single ascending intravenous (IV) doses of CBS001 Part B: Multiple ascending IV doses of CBS001


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05323110
Study type Interventional
Source Capella Bioscience Ltd
Contact
Status Terminated
Phase Phase 1
Start date April 14, 2022
Completion date August 22, 2023

See also
  Status Clinical Trial Phase
Completed NCT04327752 - Skin Adverse Reactions Occuring in Children Treated by Biotherapy for Chronic Inflammatory Disease
Recruiting NCT04334031 - Deployment o the Multidisciplinary Prospective Cohort Imminent N/A
Active, not recruiting NCT02332460 - Infusion Related Reactions in Patients Receiving Infliximab
Recruiting NCT05613712 - Chronic Inflammatory Rheumatism: Management of Comorbidities in Ambulatory Medicine